BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 23905405)

  • 1. [Treatment of constipation in chronic pain patients].
    Shimoyama N; Shimoyama M
    Masui; 2013 Jul; 62(7):822-8. PubMed ID: 23905405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approaches to the treatment of opioid-induced constipation.
    Holzer P
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1(0 1):119-27. PubMed ID: 18924451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid-induced constipation: challenges and therapeutic opportunities.
    Camilleri M
    Am J Gastroenterol; 2011 May; 106(5):835-42; quiz 843. PubMed ID: 21343919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of opioid-induced constipation.
    Prichard D; Norton C; Bharucha AE
    Br J Nurs; 2016 May 26-Jun 8; 25(10):S4-5, S8-11. PubMed ID: 27231750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
    Holder RM; Rhee D
    Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal?
    Holzer P
    Curr Pharm Des; 2012; 18(37):6010-20. PubMed ID: 22747544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylnaltrexone for the treatment of opioid-induced constipation.
    Bader S; Dürk T; Becker G
    Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):13-26. PubMed ID: 23265145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach.
    Reimer K; Hopp M; Zenz M; Maier C; Holzer P; Mikus G; Bosse B; Smith K; Buschmann-Kramm C; Leyendecker P
    Pharmacology; 2009; 83(1):10-7. PubMed ID: 18957874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
    Irving G; Pénzes J; Ramjattan B; Cousins M; Rauck R; Spierings EL; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
    J Pain; 2011 Feb; 12(2):175-84. PubMed ID: 21292168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.
    Paulson DM; Kennedy DT; Donovick RA; Carpenter RL; Cherubini M; Techner L; Du W; Ma Y; Schmidt WK; Wallin B; Jackson D
    J Pain; 2005 Mar; 6(3):184-92. PubMed ID: 15772912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
    Jansen JP; Lorch D; Langan J; Lasko B; Hermanns K; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
    J Pain; 2011 Feb; 12(2):185-93. PubMed ID: 21292169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylnaltrexone in treatment of opioid-induced constipation in a pediatric patient.
    Lee JM; Mooney J
    Clin J Pain; 2012 May; 28(4):338-41. PubMed ID: 21876436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developments in managing severe chronic pain: role of oxycodone-naloxone extended release.
    Fanelli G; Fanelli A
    Drug Des Devel Ther; 2015; 9():3811-6. PubMed ID: 26229442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans.
    Holzer P
    Neurosci Lett; 2004 May; 361(1-3):192-5. PubMed ID: 15135926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects.
    Yuan CS
    J Support Oncol; 2004; 2(2):111-7; discussion 119-22. PubMed ID: 15328815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined oral prolonged-release oxycodone and naloxone in chronic pain management.
    Mercadante S; Giarratano A
    Expert Opin Investig Drugs; 2013 Jan; 22(1):161-6. PubMed ID: 23215628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology, diagnosis, and management of opioid-induced constipation.
    Farmer AD; Holt CB; Downes TJ; Ruggeri E; Del Vecchio S; De Giorgio R
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):203-212. PubMed ID: 29870734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.
    Morlion B; Clemens KE; Dunlop W
    Clin Drug Investig; 2015 Jan; 35(1):1-11. PubMed ID: 25479959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects.
    Yuan CS
    Ann Pharmacother; 2007 Jun; 41(6):984-93. PubMed ID: 17504835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targinact--opioid pain relief without constipation?
    Drug Ther Bull; 2010 Dec; 48(12):138-41. PubMed ID: 21123290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.